Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing
|Title:||Method for reducing pain|
|Abstract:||The present invention is direct to a method of producing analgesia in a mammalian subject. The method includes administering to the subject an omega conopeptide, preferably ziconotide, in combination with an analgesic selected from the group consisting of morphine, bupivicaine, clonidine, hydromorphone, baclofen, fentanyil, buprenorphine, and sufentanil, or its pharmaceutically acceptable salts thereof, wherein the .omega.-conopeptide retains its potency and is physically and chemically compatible with the analgesic compound. A preferred route of administration is intrathecal administration, particularly continuous intrathecal infusion. The present invention is also directed to a pharmaceutical formulation comprising an omega conopeptide, preferably ziconotide, in combination with an analgesic selected from the group consisting of morphine, bupivicaine, clonidine, hydromorphone, baclofen, fentanyl, buprenorphine, and sufentanil.|
|Inventor(s):||Ellis; David J. (Los Altos, CA), Miljanich; George P. (Redwood City, CA), Shields; David E. (San Lorenzo, CA)|
|Assignee:||Elan Pharmaceuticals, Inc. (South San Francisco, CA)|
|Filing Date:||Oct 01, 2004|
|Claims:||1. A pharmaceutical formulation comprising ziconotide, an antioxidant, and morphine, wherein the concentration of ziconotide is 10-25 .mu.g/ml and the concentration of morphine is 7.5-18.75 mg/ml, wherein ziconotide retains its potency and is physically and chemically compatible with morphine. |
2. The pharmaceutical formulation according to claim 1, wherein said antioxidant is methionine.
3. The pharmaceutical formulation according to claim 1, which has pH between 4 to 4.5.
4. The pharmaceutical formulation according to claim 1, wherein the pharmaceutical formulation is suitable for intrathecal administration.
5. The pharmaceutical formulation according to claim 4, wherein the pharmaceutical formulation is suitable for continuous intrathecal infusion.
6. The pharmaceutical formulation according to claim 1, wherein said formulation is stable in a drug dispensing implantable pump at 37.degree. C. for at least 7 days.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.